AGC Biologics Launches BravoAAV and ProntoLVV Platforms for CGTs

AGC Biologics, a global biopharmaceutical CDMO, launched its BravoAAV and ProntoLVV viral vector platforms. The new platforms leverage the company’s Lentiviral vector (LVV) and Adeno-Associated Viral vector (AAV) development, manufacturing and analytical experience to offer fast, efficient and reproducible clinical and commercial GMP production and release. The company’s process and capsid-specific platform methods aim to accelerate development timelines, delivering GMP product in nine months.
 
The BravoAAV and ProntoLVV platforms have production at different scales in suspension up to 2,000 L and adhesion up to 750 L, and include prequalified scale-down models simplifying and accelerating the path to commercialization.
 
The AAV and LVV platforms include in-network plasmid DNA (pDNA) supplies (high-quality and GMP-grade), all major testing performed in-house and the use of cell factories and fixed bed bioreactor for adherent protocols, and wave and stirrer bioreactors for suspension. BravoAAV and ProntoLVV also include a comprehensive set of analytical methods pre-qualified for clinical application and ready to validate for commercial purposes, and a templated material approach to help support regulatory steps and approvals. 
 
BravoAAV and ProntoLVV are designed by the scientists at the AGC Biologics Milan site, a group with 30 years of experience building custom vector programs that scale to commercial levels and meet global regulatory standards.